Semler Scientific Inc. (SMLR) 3.92 $SMLR
Semler Scientific, Inc. Appoints Medical Device and Pharmaceutical Industry Leader Bruce J Barclay to its Board of Directors
PR Newswire - Tue May 06, 3:30PM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"
, an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the appointment of Bruce J Barclay to the company's board of directors. Mr. Barclay will also chair the board's compensation committee and serve as a member of the audit committee. Mr. Barclay recently served as president and chief executive officer and board member of Hansen Medical, Inc. He has more than 15 years of experience in leading public and private companies in the medical device and pharmaceutical industries.
Semler Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 22, 6:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler", an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today reported financial results for the first quarter ended March 31, 2014.
Semler to Report First Quarter 2014 Financial Results and Host Conference Call on April 22, 2014
PR Newswire - Tue Apr 15, 3:05PM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler", an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced that it will report first quarter 2014 financial results before the open of U.S. financial markets on April 22, 2014. Doug Murphy-Chutorian, M.D., chief executive officer of Semler will host a conference call at 10 a.m. EDT, April 22, 2014.
Semler Scientific, Inc. Announces Closing of Initial Public Offering
PR Newswire - Thu Feb 27, 11:09AM CST
Semler Scientific, Inc. (NASDAQ: SMLR), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the closing of its previously announced initial public offering of 1,430,000 shares of its common stock offered at a price to the public of $7.00 per share. The gross proceeds to Semler from the initial public offering were $10,010,000, before deducting underwriting discounts and commissions and other offering expenses. Semler has granted the representative of the underwriters a 45-day option to purchase up to 214,500 additional shares of common stock from Semler to cover over-allotments, if any.
Semler Scientific Announces Pricing of Initial Public Offering of Common Stock
PR Newswire - Thu Feb 20, 4:28PM CST
Semler Scientific, Inc. (NASDAQ: SMLR), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the pricing of its initial public offering of 1,430,000 shares of its common stock at an initial public offering price of $7.00 per share. The gross proceeds to Semler from the initial public offering are expected to be $10,010,000, before underwriting discounts and commissions and other offering expenses. In addition, Semler has granted the underwriters a 45-day option to purchase up to 214,500 additional shares of common stock from Semler to cover over-allotments, if any. Semler's common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the symbol "SMLR" on February 21, 2014.
Semler Scientific, Inc. Appoints Medical Device and Pharmaceutical Industry Leader Bruce J Barclay to its Board of Directors
PR Newswire - Tue May 06, 3:30PM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"
, an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the appointment of Bruce J Barclay to the company's board of directors. Mr. Barclay will also chair the board's compensation committee and serve as a member of the audit committee. Mr. Barclay recently served as president and chief executive officer and board member of Hansen Medical, Inc. He has more than 15 years of experience in leading public and private companies in the medical device and pharmaceutical industries. Semler Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 22, 6:00AM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"
, an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today reported financial results for the first quarter ended March 31, 2014. Semler to Report First Quarter 2014 Financial Results and Host Conference Call on April 22, 2014
PR Newswire - Tue Apr 15, 3:05PM CDT
Semler Scientific, Inc. (Nasdaq: SMLR; "Semler"
, an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced that it will report first quarter 2014 financial results before the open of U.S. financial markets on April 22, 2014. Doug Murphy-Chutorian, M.D., chief executive officer of Semler will host a conference call at 10 a.m. EDT, April 22, 2014. Semler Scientific, Inc. Announces Closing of Initial Public Offering
PR Newswire - Thu Feb 27, 11:09AM CST
Semler Scientific, Inc. (NASDAQ: SMLR), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the closing of its previously announced initial public offering of 1,430,000 shares of its common stock offered at a price to the public of $7.00 per share. The gross proceeds to Semler from the initial public offering were $10,010,000, before deducting underwriting discounts and commissions and other offering expenses. Semler has granted the representative of the underwriters a 45-day option to purchase up to 214,500 additional shares of common stock from Semler to cover over-allotments, if any.
Semler Scientific Announces Pricing of Initial Public Offering of Common Stock
PR Newswire - Thu Feb 20, 4:28PM CST
Semler Scientific, Inc. (NASDAQ: SMLR), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the pricing of its initial public offering of 1,430,000 shares of its common stock at an initial public offering price of $7.00 per share. The gross proceeds to Semler from the initial public offering are expected to be $10,010,000, before underwriting discounts and commissions and other offering expenses. In addition, Semler has granted the underwriters a 45-day option to purchase up to 214,500 additional shares of common stock from Semler to cover over-allotments, if any. Semler's common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the symbol "SMLR" on February 21, 2014.
